Foundry Partners’s Coherus Oncology CHRS Stock Holding History

Foundry Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-58,901	Closed	-$1.08M	–	419
2020 Q3	$1.08M	Sell	58,901 -653	-1%	-$12.1K	0.05%	311
2020 Q2	$1.06M	Sell	59,554 -19,098	-24%	-$323K	0.05%	300
2020 Q1	$1.28M	Hold	78,652	–	–	0.07%	275
2019 Q4	$1.42M	Buy	78,652 +6,072	+8%	+$112K	0.05%	298
2019 Q3	$1.47M	Buy	72,580 +34,000	+88%	+$679K	0.06%	288
2019 Q2	$853K	Buy	+38,580	New	+$670K	0.03%	327

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Foundry Partners's CHRS Position: Q4 2020 in Review

Foundry Partners sold out of Coherus Oncology (CHRS) in Q4 2020, closing a stake of 58,901 shares — an estimated $1.08M sold.

Foundry Partners first reported a position in CHRS in Q2 2019 and held it in 6 quarters. The position peaked at $1.47M in Q3 2019. 196 funds tracked by Wall St. Rank hold CHRS as of Q4 2020.

Foundry Partners reported no remaining Coherus Oncology position as of Q4 2020 after selling out during the quarter.
Foundry Partners sold 58,901 Coherus Oncology shares in Q4 2020, an estimated $1.08M.
Foundry Partners first reported a position in Coherus Oncology in Q2 2019 and held it in 6 quarters.
Foundry Partners's Coherus Oncology position peaked at $1.47M in Q3 2019.
196 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2020.

Based on Foundry Partners's 13F filing for Q4 2020, filed 4 Feb 2021.